Enhancing Exposure Therapy for Snake and Spider Phobias
Launched by UNIVERSITY OF TEXAS AT AUSTIN · Jun 6, 2014
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
This study tests whether exposure therapy for fear of snakes or spiders is enhanced by the addition of a brief fear retrieval trial prior to treatment, and the use of compound extinction during treatment. The goal of the study is to determine whether these behavioral techniques enhance the efficacy of exposure therapy, one of the most empirically supported treatments for anxiety disorders. Individuals between the ages of 18-65 with elevated fear of spiders or fear of snakes are randomly assigned to one of four treatment conditions (1) standard exposure therapy, (2) exposure therapy with fea...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18 to 65.
- • 2. Speaks English fluently.
- • 3. A score of 70 or higher on the Fear of Snakes/Spiders Questionnaire.
- • 4. Demonstrates avoidance during behavioral approach tests (defined as inability to put palm flat on the bottom of a tank containing a snake/spider, and inability to touch a snake/spider with a bare finger).
- Exclusion Criteria:
- • 1. Unstable dose of psychotropic medications during the 4 weeks prior to baseline assessment.
- • 2. Currently receiving exposure-based treatment for snake/spider phobia.
- • 3. Currently at risk for suicide.
About University Of Texas At Austin
The University of Texas at Austin, a leading research institution, is dedicated to advancing knowledge and innovation in the field of healthcare through rigorous clinical trials. Known for its commitment to scientific excellence, the university leverages its diverse expertise and cutting-edge facilities to conduct research that addresses critical health challenges. Collaborating with a multidisciplinary team of researchers, clinicians, and students, the University of Texas at Austin aims to translate scientific discoveries into effective treatments and interventions, ultimately enhancing patient outcomes and contributing to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Austin, Texas, United States
Patients applied
Trial Officials
Michael J Telch, PhD
Principal Investigator
University of Texas at Austin
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials